Isomorphic Labs’ financing led the way for first quarter 2025 financings, but it comes amid headwinds for the biotech sector. Biotech financing activity has been slowing down, analysts say.
Apellis Pharmaceuticals and Astellas Pharma have the first two FDA-approved therapies for geographic atrophy, but Character Biosciences claims its approach could be best in class for treating this advanced form of dry age-related macular degeneration. The biotech's Series B round will finance clinical tests of two programs, each addressing a different stage of the disease.
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Thermo Fisher Scientific agreed to acquire the Purification and Filtration business of 3M spinoff Solventum. Filters and membranes from this business segment are used globally in applications such as biopharmaceutical manufacturing.
Improving the identification and validation of disease-specific drug targets in a cell-type and patient-specific manner early on will not only reduce the failure rate and cost that is so inherent in current drug development processes but also allow the development of more effective precision medicines, improving patient outcomes.
Memorial Sloan Kettering Cancer Center partnered with AWS to accelerate its research with AI. The collaboration seeks to speed up drug discovery and increase activity within the health system’s startup accelerator.
Merck’s implementation of artificial intelligence in drug research includes analyzing years of existing Merck clinical data to help identify which drugs and drug combinations to pursue. But Merck executive Matt Studney said AI is a tool to help, not replace humans.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Applications of SandboxAQ’s large quantitative models (LQMs) technology include running simulations that identify new biomarkers and optimize clinical development of drug candidates. The company spun out of Alphabet in 2022.
BenevolentAI said it will still develop its internally discovered drugs, but will now seek partners for them earlier in their development. Going forward, BenevolentAI will focus on making its AI technologies available to support the drug R&D efforts of its partners.
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
Halozyme’s offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a cost-saving corporate restructuring.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Pharmaceutical and biotech companies are using generative AI to predict drug-target interactions, optimize lead compounds, and generate novel molecular structures. During the recent MedCity News INVEST Digital Health conference, a panel discussed these applications and more.
Respiratory disease and immunology are the initial focus areas of GSK’s new drug discovery partnership with Flagship Pioneering. A similar Flagship alliance with Pfizer recently announced it is pursuing novel obesity treatments.
Pepper Bio has licensed rights to lerociclib, a molecule that G1 Therapeutics designed to offer dosing and safety advantages over approved therapies in the same drug class. EQRx previously held rights to the drug, but returned them after the company was acquired last year.
Diagonal Therapeutics develops agonist antibodies to treat rare cardiovascular conditions. Using artificial intelligence, the startup’s technology sorts through billions of antibody/receptor combinations to identify the ones that reactivate signaling pathways lost to disease.
Exscientia’s termination of CEO Andrew Hopkins is for cause and effective immediately. Grounds for termination include misconduct or behavior that brings Hopkins or the company into disrepute, according to his employment agreement.